SCHEMBL6964262

SCHEMBL6964262

Nc1ccc(C(N)C(=O)OCc2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.48
ALDH1A1 P00352 4/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
RAB9A P51151 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 2/20 0.46
MAOB P27338 2/20 0.46
MAPK1 P28482 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
GAA P10253 1/20 0.46
MAOA P21397 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPC1 O15118 1/20 0.45
LTA4H P09960 1/20 0.45
LAP3 P28838 1/20 0.45
F2 P00734 1/20 0.44
PLAU P00749 1/20 0.44
PLAT P00750 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745793 0.90 ALDH1A1 (0.53) ALDH1A1L3MBTL1KMT2AMAPK1SLC6A2
SCHEMBL8804399 0.90 ALDH1A1 (0.53) ALDH1A1L3MBTL1KMT2AMAPK1SLC6A2
SCHEMBL11472824 0.90 ALDH1A1 (0.53) ALDH1A1L3MBTL1KMT2AMAPK1SLC6A2
Hydrochloric Acid SCHEMBL10886394 0.88 ALDH1A1 (0.52) ALDH1A1L3MBTL1KMT2AMAPK1SLC6A2
Hydrochloric Acid SCHEMBL5552487 0.86 ALDH1A1 (0.46) ALDH1A1L3MBTL1RAB9AKMT2AMAPK1
SCHEMBL31652735 0.86 CNR2 (0.47) CNR2ALDH1A1L3MBTL1KMT2AMAPK1
SCHEMBL29261445 0.86 CNR2 (0.47) CNR2ALDH1A1L3MBTL1KMT2AMAPK1
SCHEMBL5456496 0.86 NR4A1 (0.53) ALDH1A1L3MBTL1RAB9AKMT2AMAPT
Hydrochloric Acid SCHEMBL31652655 0.84 CNR2 (0.46) CNR2ALDH1A1L3MBTL1KMT2AMAPK1
SCHEMBL10861854 0.84 LTA4H (0.63) L3MBTL1RAB9AMAPTMAOBSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345715-B2 Biologically active molecules, conjugates thereof, and therapeutic uses REGENERON PHARMACEUTICALS, INC. (US) 2022-05-31 US disclosed
US-20200277306-A1 BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES REGENERON PHARMACEUTICALS, INC. 2020-09-03 US disclosed
US-10570151-B2 Biologically active molecules, conjugates thereof, and therapeutic uses REGENERON PHARMACEUTICALS, INC. (US) 2020-02-25 US disclosed
US-20160030591-A1 BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES REGENERON PHARMACEUTICALS, INC. 2016-02-04 US disclosed
EP-2968593-A1 BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES Regeneron Pharmaceuticals, Inc. (US) 2016-01-20 EP disclosed
WO-2014145090-A1 BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES REGENERON PHARMACEUTICALS, INC. (US) 2014-09-18 WO disclosed
EP-0713483-B1 AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES ASTRAZENECA AB (SE) 2003-01-15 EP disclosed
US-6030985-A Amidine derivatives with nitric oxide synthetase activities ASTRA AKTIEBOLAG (SE) 2000-02-29 US disclosed
US-5807885-A Amidine derivatives with nitric oxide synthetase activities ASTRA AKTIEBOLAG (SE) 1998-09-15 US disclosed
EP-0713483-A1 AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES Astra Aktiebolag (SE) 1996-05-29 EP disclosed
WO-1995005363-A1 AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES ASTRA AKTIEBOLAG (SE) 1995-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10570151-B2 Biologically active molecules, conjugates thereof, and therapeutic uses CD47, CD44, ACP1 CNR2 4095/4885ALDH1A1 934/4885L3MBTL1 1131/4885
US-20160030591-A1 BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES CD47, CD44, ACP1 CNR2 4095/4885ALDH1A1 934/4885L3MBTL1 1131/4885
US-11345715-B2 Biologically active molecules, conjugates thereof, and therapeutic uses CD47, CD44, ACP1 CNR2 4095/4885ALDH1A1 934/4885L3MBTL1 1131/4885
US-20200277306-A1 BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES CD47, CD44, ACP1 CNR2 4095/4885ALDH1A1 934/4885L3MBTL1 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.